Company intelligence / Profile preview

BioCurie

Wilmington, Delaware, United Statesbiocurie.com ↗

Ownership: Private
Development stage: Preclinical

Overview

BioCurie's AI-driven SaaS platform creates digital twins of cell and gene therapy manufacturing processes, enabling millions of virtual experiments to optimize production. This approach aims to reduce time, cost, and risk while improving quality and consistency in the manufacture of advanced therapies. The company is pre-commercial but has won innovation awards and is engaged in pilot partnerships.

Modalities: Cell therapyGene therapyRNA therapy (enabling technologies, not direct therapeutics)
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Cure Exchange Challenge residency at Cure’s New York City campus incubator

Beyond the preview

Go deeper on BioCurie.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCurie.

Explore the full profile